StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research note issued to investors on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
Several other research analysts have also recently weighed in on the stock. HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price target for the company. in a report on Tuesday, June 25th. Alliance Global Partners reiterated a neutral rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Finally, Maxim Group reaffirmed a hold rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.
Check Out Our Latest Stock Analysis on ALIM
Alimera Sciences Price Performance
Alimera Sciences (NASDAQ:ALIM – Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. The business had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. On average, research analysts expect that Alimera Sciences will post -0.13 EPS for the current year.
Institutional Trading of Alimera Sciences
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Deltec Asset Management LLC acquired a new position in shares of Alimera Sciences during the 2nd quarter worth approximately $690,000. Vanguard Group Inc. grew its position in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after acquiring an additional 396,506 shares during the period. Ancora Advisors LLC acquired a new position in shares of Alimera Sciences during the 1st quarter worth about $915,000. Fifth Lane Capital LP bought a new stake in shares of Alimera Sciences in the 1st quarter valued at about $83,000. Finally, Hillsdale Investment Management Inc. bought a new stake in shares of Alimera Sciences in the 1st quarter valued at about $169,000. Institutional investors own 99.83% of the company’s stock.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Read More
- Five stocks we like better than Alimera Sciences
- Upcoming IPO Stock Lockup Period, Explained
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- Pros And Cons Of Monthly Dividend Stocks
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- Top Stocks Investing in 5G Technology
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.